In the present study, we analyse the expression of CTAs NY-ESO-1, PRAME, and SSX2 in a large and well-characterised cohort of high-risk soft-tissue sarcoma patients with long-term follow-up and correlate our findings with the presence of TILs, clinical tumour characteristics, and survival data. This evidence concerns the gene PRAME and soft tissue sarcoma.